Prostate Cancer - Results from #520

Real-world evidence of 18F-fluciclovine Positron emission tomography/computed tomography performance for recurrent prostate cancer in the Veterans Affairs Health System. July 23, 2024

The Benefit of Combining Docetaxel with Androgen Deprivation Therapy in Localized and Metastatic Hormone-sensitive Prostate Cancer is Predicted by ERG Expression: An Analysis of Two GETUG Phase 3 Trials. July 23, 2024

Contemporary Treatment Patterns and Oncological Outcomes of Metastatic Hormone-sensitive Prostate Cancer and First- to Sixth- line Metastatic Castration-resistant Prostate Cancer Patients. July 23, 2024

A 2-year prospective evaluation of the Prostate Health Index in guiding biopsy decisions in a large cohort. July 23, 2024

Prostate Cancer Awareness in the Middle East: A Cross-Sectional International Study. July 23, 2024

Targeting androgen receptor degradation with PROTACs from bench to bedside. July 22, 2024

Discovery of a Series of Orally Bioavailable Androgen Receptor Degraders for the Treatment of Prostate Cancer. July 22, 2024

Comparison of synthesized and acquired high b-value diffusion-weighted MRI for detection of prostate cancer. July 22, 2024

61Cu-PSMA-Targeted PET for Prostate Cancer: From Radiotracer Development to First-in-Human Imaging. July 22, 2024

Notch signaling suppresses neuroendocrine differentiation and alters the immune microenvironment in advanced prostate cancer. July 22, 2024

PSA, an outdated biomarker for prostate cancer: in search of a more specific biomarker, citrate takes the spotlight. July 22, 2024

Acute BRCAness Induction and AR Signaling Blockage through CDK12/7/9 Degradation Enhances PARP Inhibitor Sensitivity in Prostate Cancer. July 22, 2024

Neoadjuvant Exercise Therapy in Prostate Cancer: A Phase 1, Decentralized Nonrandomized ControlledTrial. July 22, 2024

Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry. July 22, 2024

The 30th Annual Prostate Cancer Foundation Scientific Retreat Report. July 19, 2024

Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer. July 19, 2024

PIK3/Akt/mTOR pathway alterations in metastatic castration-sensitive prostate cancer. July 19, 2024

Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer. July 19, 2024

Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement. July 19, 2024

Target Volume Optimization for Localized Prostate Cancer. July 19, 2024

Page 27 of 1435